MTIX Micro Therapeutics (MM)

ev3 and Micro Therapeutics to Report 2005 Second Quarter Financial Results and Host Joint Conference Call on August 2, 2005 PLYMOUTH, Minn. and IRVINE, Calif., July 27 /PRNewswire-FirstCall/ -- ev3 Inc. (NASDAQ:EVVV) and its majority-owned subsidiary Micro Therapeutics, Inc. (MTI) (NASDAQ:MTIX), today jointly announced that each company will release its 2005 second quarter financial results on August 2, 2005 after the close of regular market trading hours. The companies will host a joint conference call the same day at 5:00 p.m. EDT (4:00 p.m. CDT; 2:00 p.m. PDT). Management from ev3 first will review its financial and operating results and future outlook. A question and answer session about ev3 will follow. At approximately 5:25 p.m. EDT, MTI management will review its financial and operating results and provide its future outlook. The call then will be opened for questions about MTI. The conference call will be available to interested parties through a live audio webcast at http://www.ev3.net/ as well as http://www.1mti.com/ where it will be archived and accessible for approximately one year. About Micro Therapeutics, Inc. MTI develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of cerebral vascular disorders. The company's primary focus is on catheter based technologies and products for the interventional neuroradiology market. About ev3 Inc. ev3 Inc. is a global medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders. DATASOURCE: Micro Therapeutics, Inc.; ev3 Inc. CONTACT: Pat Spangler, CFO of ev3 Inc. +1-763-398-7000; or Marian Briggs or Nancy Johnson of Padilla Speer Beardsley, +1-612-455-1700, for ev3 Inc.; or Thomas C. Wilder, CEO of Micro Therapeutics, Inc., +1-949-837-3700; or Rob Whetstone or Robert Jaffe of PondelWilkinson Inc., +1-310-279-5980, for Micro Therapeutics, Inc. Web site: http://www.1mti.com/ http://www.ev3.net/

Copyright